TargetMol

GIP (3-42), human

Product Code:
 
TAR-T37589
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T37589-1mg1mg£228.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37589-5mg5mg£462.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37589-10mg10mg£630.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37589-25mg25mg£946.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37589-50mg50mg£1,267.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T37589-100mg100mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Gastric inhibitory polypeptide (3-42) represents the major physiological degradation product of gastric inhibitory polypeptide (GIP). It is generated by proteolytic processing of GIP by dipeptidyl peptidase IV (DPP IV).
CAS:
1802086-25-4
Formula:
C214H324N58O63S
Molecular Weight:
4749.35
Pathway:
Tyrosine Kinase/Adaptors
Purity:
0.98
SMILES:
N/A
Target:
IGF-1R

References

Gault VA, et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol. 2002 Nov;175(2):525-33.